Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 177

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Chronic divalproex sodium use and brain atrophy in Alzheimer disease

Open access
Fleisher, A.S., Truran, D., Mai, J.T., Langbaum, J.B.S., Aisen, P.S., Cummings, J.L., Jack, C.R., Weiner, M.W., Thomas, R.G., Schneider, L.S., Tariot, P.N., For the Alzheimer's Disease Cooperative Study·2011·Neurology

Abstract

Objective: We evaluated the effect of the divalproex sodium formulation of valproic acid on brain volumes using MRI in people with mild to moderate Alzheimer disease (AD) and assessed for changes associated with behavioral and cognitive effects. Methods: Eighty-nine of 313 participants randomized to divalproex or placebo in a 24-month, parallel-group trial received MRI scans at baseline and 12 months. Interval MRI annual percent changes in whole brain, ventricular, and hippocampal volumes were the primary outcomes of interest. Change from baseline in clinical outcomes was assessed at 6-month intervals. Results: There were no baseline differences between active treatment and placebo groups in age, education, brain volumes, clinical rating scores, or APOE ϵ4 carrier status. The group treated with divalproex showed a greater rate of decline in left and right hippocampal and brain volumes (−10.9% and −12.4% vs −5.6% and −6.3%, and −3.5% vs −1.4%, respectively), and a greater rate of ventricular expansion (24.5% vs 9.9%) ( p < 0.001). Mini-Mental State Examination scores showed a more rapid decline with divalproex through month 12 (placebo = −2.0 ± 4.3, divalproex = −3.9 ± 4.0) ( p = 0.037), although there were no changes on other cognitive, behavioral, or functional ratings at 12 and 24 months. Conclusions: Divalproex treatment was associated with accelerated brain volume loss over 1 year and perhaps with greater cognitive impairment. The long-term clinical effects of these changes are not known. GLOSSARY : Aβ= : amyloid β-peptide; AD= : Alzheimer disease; ADAS-cog= : Alzheimer's Disease Assessment Scale–cognitive subscale; ADCS= : Alzheimer's Disease Cooperative Study; ADCS-ADL= : Alzheimer's Disease Cooperative Study activities of daily living; ADCS-CGIC= : Alzheimer's Disease Cooperative Study Clinical Global Impression of Change scale; ADNI= : Alzheimer's Disease Neuroimaging Initiative; ANCOVA= : analysis of covariance; BSI= : boundary shift integral; CDR= : Clinical Dementia Rating; CDR-SB= : CDR sum of boxes score; CMAI= : Cohen Mansfield Agitation Inventory; GEE= : generalized estimating equation; ITT= : intent-to-treat analysis; MMSE= : Mini-Mental State Examination; NPI= : Neuropsychiatric Inventory; QOL-AD= : Alzheimer's Disease Quality of Life scale; SFVAMC= : San Francisco Veterans Administration Medical Center; TIV= : total intracranial volume; VPA= : valproic acid

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0b013e318230a16c

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 177

Metadata

Authors
Fleisher, A. S., Truran, D., Mai, J. T., Langbaum, J. B. S., Aisen, P. S., Cummings, J. L., Jack, C. R., Weiner, M. W., Thomas, R. G., Schneider, L. S., Tariot, P. N., & Study, F. T. A. D. C.
Venue
Neurology
Published
2011-09-27
Volume
77
Issue
13
Pages
1263-1271
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W1965598001
Cited by
177
References
7
FWCI
7.29
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chronic divalproex sodium use and brain atrophy in Alzheimer disease. https://app.cochat.ai/papers/10.1212/wnl.0b013e318230a16c
The paper
Fleisher, A. S., Truran, D., Mai, J. T., Langbaum, J. B. S., Aisen, P. S., Cummings, J. L., Jack, C. R., Weiner, M. W., Thomas, R. G., Schneider, L. S., Tariot, P. N., & Study, F. T. A. D. C. (2011). Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology. https://doi.org/10.1212/wnl.0b013e318230a16c

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.